Resources Phase-III-IV 
The Pharma Data
JANUARY 7, 2021
7, 2020 — For patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation, sitagliptin combined with tacrolimus and sirolimus results in a low incidence of grade II to IV acute graft-versus-host disease (GVHD) by day 100, according to a study published in the Jan. More News Resources. THURSDAY, Jan.
XTalks
JUNE 16, 2023
With an active role in research, the National Kidney Foundation strives to reach at-risk populations, as well as early-stage and late-stage patients, providing them with resources to manage the disease effectively. The Innovation Fund has also recently invested in Relavo and Medigo to further technological advancements in renal health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JULY 28, 2022
A study published in the Journal of the American Medical Association has analyzed 338 Phase III and Phase IV clinical trials and revealed that 12.4 percent of people with developmental or intellectual disabilities and 1.8
The Pharma Data
APRIL 28, 2021
Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001). With both IV and oral formulations in development, Fosmanogepix may allow for the transition from IV to oral, thus potentially enabling, for the benefit of patients, the continuation of treatment outside the hospital.
The Pharma Data
OCTOBER 1, 2021
The approval of CIBINQO in Japan was based on the results from 1,513 patients across four Phase 3 studies, ranging from 12 to 16 weeks of treatment, and a long-term extension study from a robust clinical trial program. iii,iv In Japan, AD affects approximately 3% of adults and 13% of children.
The Pharma Data
JANUARY 20, 2021
CytomX expects to use any remaining net proceeds from this offering for capital expenditures, working capital and other general corporate purposes.
The Pharma Data
OCTOBER 14, 2020
Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2). i,ii,iii,iv.
Expert insights. Personalized for you.
52 
Let's personalize your content